Page 51 - Read Online

Page 123 Waller et al. J Transl Genet Genom 2021;5:112-23 I http://dx.doi.org/10.20517/jtgg.2021.09

2019;33:2324-30.
23. Thomas A, Camp NJ, Farnham JM, Allen-Brady K, Cannon-Albright LA. Shared genomic segment analysis. Mapping disease
predisposition genes in extended pedigrees using SNP genotype assays. Ann Hum Genet 2008;72:279-87.
24. Knight S, Abo RP, Abel HJ, et al. Shared genomic segment analysis: the power to find rare disease variants. Ann Hum Genet 2012;76:500-
9.
25. McClellan J, King MC. Genetic heterogeneity in human disease. Cell 2010;141:210-7.
26. Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet
1995;11:241-7.
27. Hanson HA, Leiser CL, Madsen MJ, et al. Family Study Designs Informed by Tumor Heterogeneity and Multi-Cancer Pleiotropies: The
Power of the Utah Population Database. Cancer Epidemiol Biomarkers Prev 2020;29:807-15.
28. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J
Hum Genet 2007;81:559-75.
29. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene
2008;27:6920-9.
30. Xu L, Lin DC, Yin D, Koeffler HP. An emerging role of PARK2 in cancer. J Mol Med (Berl) 2014;92:31-42.31. Xiong D, Wang Y, Kupert
E, et al. A recurrent mutation in PARK2 is associated with familial lung cancer. Am J Hum Genet 2015;96:301-8.
31. Xiong D, Wang Y, Kupert E, et al. A recurrent mutation in PARK2 is associated with familial lung cancer. Am J Hum Genet 2015;96:301-
8.